nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—uterine cancer	0.367	1	CbGaD
Carvedilol—XDH—Carboplatin—uterine cancer	0.0689	0.213	CbGbCtD
Carvedilol—XDH—Doxorubicin—uterine cancer	0.0395	0.122	CbGbCtD
Carvedilol—CYP1A1—Progesterone—uterine cancer	0.0377	0.117	CbGbCtD
Carvedilol—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0229	0.071	CbGbCtD
Carvedilol—PTGS1—Etoposide—uterine cancer	0.0169	0.0523	CbGbCtD
Carvedilol—CYP1A2—Progesterone—uterine cancer	0.0169	0.0522	CbGbCtD
Carvedilol—CYP2C9—Progesterone—uterine cancer	0.0152	0.047	CbGbCtD
Carvedilol—ABCB1—Progesterone—uterine cancer	0.0147	0.0456	CbGbCtD
Carvedilol—CYP2D6—Progesterone—uterine cancer	0.0139	0.043	CbGbCtD
Carvedilol—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0133	0.0413	CbGbCtD
Carvedilol—CYP2E1—Etoposide—uterine cancer	0.013	0.0404	CbGbCtD
Carvedilol—ABCB1—Dactinomycin—uterine cancer	0.0117	0.0362	CbGbCtD
Carvedilol—CYP3A4—Progesterone—uterine cancer	0.00883	0.0273	CbGbCtD
Carvedilol—CYP1A2—Etoposide—uterine cancer	0.00754	0.0233	CbGbCtD
Carvedilol—ABCB1—Etoposide—uterine cancer	0.00659	0.0204	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—uterine cancer	0.0045	0.0139	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—uterine cancer	0.00424	0.0131	CbGbCtD
Carvedilol—NPPB—artery—uterine cancer	0.00417	0.042	CbGeAlD
Carvedilol—CYP3A4—Etoposide—uterine cancer	0.00395	0.0122	CbGbCtD
Carvedilol—GJA1—oviduct—uterine cancer	0.00365	0.0368	CbGeAlD
Carvedilol—SELE—artery—uterine cancer	0.00281	0.0284	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—uterine cancer	0.00269	0.00834	CbGbCtD
Carvedilol—VCAM1—artery—uterine cancer	0.00259	0.0261	CbGeAlD
Carvedilol—HIF1A—artery—uterine cancer	0.00249	0.0251	CbGeAlD
Carvedilol—GJA1—artery—uterine cancer	0.00242	0.0243	CbGeAlD
Carvedilol—NPPB—myometrium—uterine cancer	0.00201	0.0203	CbGeAlD
Carvedilol—NDUFC2—exocrine gland—uterine cancer	0.00183	0.0185	CbGeAlD
Carvedilol—NPPB—smooth muscle tissue—uterine cancer	0.00152	0.0153	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Medroxyprogesterone Acetate—uterine cancer	0.00145	0.423	CbGdCrCtD
Carvedilol—SELE—myometrium—uterine cancer	0.00136	0.0137	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Progesterone—uterine cancer	0.00126	0.369	CbGdCrCtD
Carvedilol—VCAM1—myometrium—uterine cancer	0.00125	0.0126	CbGeAlD
Carvedilol—HIF1A—myometrium—uterine cancer	0.0012	0.0121	CbGeAlD
Carvedilol—GJA1—myometrium—uterine cancer	0.00117	0.0118	CbGeAlD
Carvedilol—SELE—epithelium—uterine cancer	0.00107	0.0108	CbGeAlD
Carvedilol—SELE—uterine cervix—uterine cancer	0.00106	0.0107	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—uterine cancer	0.00103	0.0104	CbGeAlD
Carvedilol—NDUFC2—myometrium—uterine cancer	0.00102	0.0102	CbGeAlD
Carvedilol—SELE—renal system—uterine cancer	0.00099	0.00997	CbGeAlD
Carvedilol—VCAM1—epithelium—uterine cancer	0.000981	0.00989	CbGeAlD
Carvedilol—VCAM1—uterine cervix—uterine cancer	0.000973	0.0098	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—uterine cancer	0.000946	0.00953	CbGeAlD
Carvedilol—HIF1A—epithelium—uterine cancer	0.000944	0.00951	CbGeAlD
Carvedilol—HIF1A—uterine cervix—uterine cancer	0.000936	0.00943	CbGeAlD
Carvedilol—VCAM1—decidua—uterine cancer	0.000927	0.00934	CbGeAlD
Carvedilol—SELE—mammalian vulva—uterine cancer	0.000925	0.00933	CbGeAlD
Carvedilol—VEGFA—myometrium—uterine cancer	0.000922	0.00929	CbGeAlD
Carvedilol—GJA1—epithelium—uterine cancer	0.000916	0.00923	CbGeAlD
Carvedilol—VCAM1—renal system—uterine cancer	0.00091	0.00917	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—uterine cancer	0.00091	0.00917	CbGeAlD
Carvedilol—GJA1—uterine cervix—uterine cancer	0.000908	0.00915	CbGeAlD
Carvedilol—HIF1A—decidua—uterine cancer	0.000892	0.00899	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—uterine cancer	0.000883	0.00889	CbGeAlD
Carvedilol—SELE—uterus—uterine cancer	0.000882	0.00888	CbGeAlD
Carvedilol—VCAM1—endometrium—uterine cancer	0.00088	0.00887	CbGeAlD
Carvedilol—HIF1A—renal system—uterine cancer	0.000876	0.00882	CbGeAlD
Carvedilol—GJA1—decidua—uterine cancer	0.000865	0.00872	CbGeAlD
Carvedilol—VCAM1—mammalian vulva—uterine cancer	0.000851	0.00858	CbGeAlD
Carvedilol—GJA1—renal system—uterine cancer	0.00085	0.00856	CbGeAlD
Carvedilol—HIF1A—endometrium—uterine cancer	0.000847	0.00853	CbGeAlD
Carvedilol—GJA1—endometrium—uterine cancer	0.000821	0.00828	CbGeAlD
Carvedilol—HIF1A—mammalian vulva—uterine cancer	0.000819	0.00825	CbGeAlD
Carvedilol—VCAM1—uterus—uterine cancer	0.000811	0.00817	CbGeAlD
Carvedilol—NDUFC2—epithelium—uterine cancer	0.000797	0.00803	CbGeAlD
Carvedilol—GJA1—mammalian vulva—uterine cancer	0.000795	0.00801	CbGeAlD
Carvedilol—SELE—female reproductive system—uterine cancer	0.000793	0.00799	CbGeAlD
Carvedilol—NDUFC2—uterine cervix—uterine cancer	0.000791	0.00797	CbGeAlD
Carvedilol—HIF1A—uterus—uterine cancer	0.00078	0.00786	CbGeAlD
Carvedilol—PTGS1—oviduct—uterine cancer	0.000774	0.0078	CbGeAlD
Carvedilol—GJA1—uterus—uterine cancer	0.000757	0.00763	CbGeAlD
Carvedilol—NDUFC2—decidua—uterine cancer	0.000753	0.00759	CbGeAlD
Carvedilol—NDUFC2—renal system—uterine cancer	0.00074	0.00745	CbGeAlD
Carvedilol—VCAM1—female reproductive system—uterine cancer	0.000729	0.00735	CbGeAlD
Carvedilol—SELE—female gonad—uterine cancer	0.000721	0.00727	CbGeAlD
Carvedilol—VEGFA—uterine cervix—uterine cancer	0.000717	0.00723	CbGeAlD
Carvedilol—SELE—vagina—uterine cancer	0.000717	0.00722	CbGeAlD
Carvedilol—NDUFC2—endometrium—uterine cancer	0.000715	0.0072	CbGeAlD
Carvedilol—GJA1—Progesterone—Medroxyprogesterone Acetate—uterine cancer	0.00071	0.207	CbGdCrCtD
Carvedilol—HIF1A—female reproductive system—uterine cancer	0.000701	0.00707	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—uterine cancer	0.000697	0.00702	CbGeAlD
Carvedilol—NDUFC2—mammalian vulva—uterine cancer	0.000692	0.00697	CbGeAlD
Carvedilol—VEGFA—decidua—uterine cancer	0.000683	0.00688	CbGeAlD
Carvedilol—GJA1—female reproductive system—uterine cancer	0.00068	0.00686	CbGeAlD
Carvedilol—VCAM1—female gonad—uterine cancer	0.000663	0.00668	CbGeAlD
Carvedilol—VCAM1—vagina—uterine cancer	0.000659	0.00664	CbGeAlD
Carvedilol—NDUFC2—uterus—uterine cancer	0.000659	0.00664	CbGeAlD
Carvedilol—VEGFA—endometrium—uterine cancer	0.000649	0.00654	CbGeAlD
Carvedilol—XDH—uterine cervix—uterine cancer	0.000638	0.00643	CbGeAlD
Carvedilol—HIF1A—female gonad—uterine cancer	0.000638	0.00643	CbGeAlD
Carvedilol—HIF1A—vagina—uterine cancer	0.000634	0.00639	CbGeAlD
Carvedilol—VEGFA—mammalian vulva—uterine cancer	0.000627	0.00632	CbGeAlD
Carvedilol—ADRB3—female reproductive system—uterine cancer	0.000624	0.00628	CbGeAlD
Carvedilol—GJA1—female gonad—uterine cancer	0.000619	0.00624	CbGeAlD
Carvedilol—GJA1—vagina—uterine cancer	0.000615	0.0062	CbGeAlD
Carvedilol—VEGFA—uterus—uterine cancer	0.000598	0.00602	CbGeAlD
Carvedilol—XDH—renal system—uterine cancer	0.000597	0.00602	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—uterine cancer	0.000592	0.00597	CbGeAlD
Carvedilol—XDH—endometrium—uterine cancer	0.000577	0.00582	CbGeAlD
Carvedilol—ADRB3—female gonad—uterine cancer	0.000567	0.00572	CbGeAlD
Carvedilol—XDH—mammalian vulva—uterine cancer	0.000558	0.00563	CbGeAlD
Carvedilol—NDUFC2—female gonad—uterine cancer	0.000539	0.00543	CbGeAlD
Carvedilol—NDUFC2—vagina—uterine cancer	0.000536	0.0054	CbGeAlD
Carvedilol—PTGS1—artery—uterine cancer	0.000513	0.00517	CbGeAlD
Carvedilol—VEGFA—female gonad—uterine cancer	0.000489	0.00493	CbGeAlD
Carvedilol—VEGFA—vagina—uterine cancer	0.000486	0.0049	CbGeAlD
Carvedilol—XDH—female reproductive system—uterine cancer	0.000478	0.00482	CbGeAlD
Carvedilol—ADRA1D—epithelium—uterine cancer	0.000473	0.00476	CbGeAlD
Carvedilol—SELE—lymph node—uterine cancer	0.000464	0.00467	CbGeAlD
Carvedilol—ADRA1B—renal system—uterine cancer	0.000448	0.00451	CbGeAlD
Carvedilol—XDH—vagina—uterine cancer	0.000433	0.00436	CbGeAlD
Carvedilol—VCAM1—lymph node—uterine cancer	0.000427	0.0043	CbGeAlD
Carvedilol—HIF1A—lymph node—uterine cancer	0.00041	0.00413	CbGeAlD
Carvedilol—GJA1—lymph node—uterine cancer	0.000398	0.00401	CbGeAlD
Carvedilol—ADRA1D—female reproductive system—uterine cancer	0.000351	0.00354	CbGeAlD
Carvedilol—NDUFC2—lymph node—uterine cancer	0.000346	0.00349	CbGeAlD
Carvedilol—KCNH2—myometrium—uterine cancer	0.000334	0.00336	CbGeAlD
Carvedilol—ADRA2C—myometrium—uterine cancer	0.000329	0.00332	CbGeAlD
Carvedilol—VEGFA—lymph node—uterine cancer	0.000314	0.00317	CbGeAlD
Carvedilol—ADRA1A—epithelium—uterine cancer	0.000271	0.00273	CbGeAlD
Carvedilol—ADRA2A—myometrium—uterine cancer	0.000263	0.00265	CbGeAlD
Carvedilol—KCNH2—uterine cervix—uterine cancer	0.00026	0.00262	CbGeAlD
Carvedilol—ADRA2C—uterine cervix—uterine cancer	0.000256	0.00258	CbGeAlD
Carvedilol—ADRB1—female reproductive system—uterine cancer	0.000255	0.00257	CbGeAlD
Carvedilol—ADRA1A—renal system—uterine cancer	0.000252	0.00254	CbGeAlD
Carvedilol—ADRA2C—decidua—uterine cancer	0.000244	0.00246	CbGeAlD
Carvedilol—KCNH2—renal system—uterine cancer	0.000243	0.00245	CbGeAlD
Carvedilol—ADRA2C—renal system—uterine cancer	0.00024	0.00242	CbGeAlD
Carvedilol—KCNH2—endometrium—uterine cancer	0.000235	0.00237	CbGeAlD
Carvedilol—ADRA2C—endometrium—uterine cancer	0.000232	0.00234	CbGeAlD
Carvedilol—ADRA2C—mammalian vulva—uterine cancer	0.000224	0.00226	CbGeAlD
Carvedilol—CYP1A1—epithelium—uterine cancer	0.000221	0.00223	CbGeAlD
Carvedilol—CYP1A1—uterine cervix—uterine cancer	0.000219	0.00221	CbGeAlD
Carvedilol—KCNH2—uterus—uterine cancer	0.000217	0.00218	CbGeAlD
Carvedilol—ADRA2C—uterus—uterine cancer	0.000214	0.00215	CbGeAlD
Carvedilol—CYP1A2—renal system—uterine cancer	0.000208	0.0021	CbGeAlD
Carvedilol—CYP1A1—renal system—uterine cancer	0.000205	0.00207	CbGeAlD
Carvedilol—ADRA2A—uterine cervix—uterine cancer	0.000205	0.00206	CbGeAlD
Carvedilol—ADRA2A—decidua—uterine cancer	0.000195	0.00196	CbGeAlD
Carvedilol—KCNH2—female reproductive system—uterine cancer	0.000195	0.00196	CbGeAlD
Carvedilol—PTGS1—epithelium—uterine cancer	0.000194	0.00196	CbGeAlD
Carvedilol—PTGS1—uterine cervix—uterine cancer	0.000193	0.00194	CbGeAlD
Carvedilol—CYP1A1—mammalian vulva—uterine cancer	0.000192	0.00193	CbGeAlD
Carvedilol—PTGS1—smooth muscle tissue—uterine cancer	0.000187	0.00189	CbGeAlD
Carvedilol—CYP2E1—renal system—uterine cancer	0.000187	0.00189	CbGeAlD
Carvedilol—ADRA2A—endometrium—uterine cancer	0.000185	0.00186	CbGeAlD
Carvedilol—CYP1A1—uterus—uterine cancer	0.000183	0.00184	CbGeAlD
Carvedilol—PTGS1—renal system—uterine cancer	0.00018	0.00182	CbGeAlD
Carvedilol—ADRA2A—mammalian vulva—uterine cancer	0.000179	0.0018	CbGeAlD
Carvedilol—KCNH2—female gonad—uterine cancer	0.000177	0.00179	CbGeAlD
Carvedilol—KCNH2—vagina—uterine cancer	0.000176	0.00177	CbGeAlD
Carvedilol—ADRA2C—female gonad—uterine cancer	0.000175	0.00176	CbGeAlD
Carvedilol—PTGS1—endometrium—uterine cancer	0.000174	0.00176	CbGeAlD
Carvedilol—ADRA2C—vagina—uterine cancer	0.000174	0.00175	CbGeAlD
Carvedilol—ADRA2A—uterus—uterine cancer	0.000171	0.00172	CbGeAlD
Carvedilol—PTGS1—mammalian vulva—uterine cancer	0.000169	0.0017	CbGeAlD
Carvedilol—CYP1A1—female reproductive system—uterine cancer	0.000164	0.00166	CbGeAlD
Carvedilol—PTGS1—uterus—uterine cancer	0.000161	0.00162	CbGeAlD
Carvedilol—CYP2C9—female reproductive system—uterine cancer	0.000158	0.00159	CbGeAlD
Carvedilol—ADRA2A—female reproductive system—uterine cancer	0.000153	0.00154	CbGeAlD
Carvedilol—CYP3A4—renal system—uterine cancer	0.000151	0.00152	CbGeAlD
Carvedilol—CYP2E1—female reproductive system—uterine cancer	0.00015	0.00151	CbGeAlD
Carvedilol—CYP1A1—female gonad—uterine cancer	0.00015	0.00151	CbGeAlD
Carvedilol—CYP1A1—vagina—uterine cancer	0.000149	0.0015	CbGeAlD
Carvedilol—CYP2D6—renal system—uterine cancer	0.000148	0.00149	CbGeAlD
Carvedilol—ABCB1—myometrium—uterine cancer	0.000146	0.00148	CbGeAlD
Carvedilol—PTGS1—female reproductive system—uterine cancer	0.000144	0.00146	CbGeAlD
Carvedilol—ADRA2A—female gonad—uterine cancer	0.000139	0.00141	CbGeAlD
Carvedilol—ADRA2A—vagina—uterine cancer	0.000139	0.0014	CbGeAlD
Carvedilol—PTGS1—female gonad—uterine cancer	0.000131	0.00132	CbGeAlD
Carvedilol—PTGS1—vagina—uterine cancer	0.000131	0.00132	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—uterine cancer	0.000121	0.00122	CbGeAlD
Carvedilol—CYP2D6—female reproductive system—uterine cancer	0.000119	0.0012	CbGeAlD
Carvedilol—ABCB1—epithelium—uterine cancer	0.000115	0.00116	CbGeAlD
Carvedilol—ABCB1—uterine cervix—uterine cancer	0.000114	0.00115	CbGeAlD
Carvedilol—KCNH2—lymph node—uterine cancer	0.000114	0.00115	CbGeAlD
Carvedilol—ADRA2C—lymph node—uterine cancer	0.000112	0.00113	CbGeAlD
Carvedilol—ABCB1—decidua—uterine cancer	0.000109	0.00109	CbGeAlD
Carvedilol—CYP2D6—female gonad—uterine cancer	0.000108	0.00109	CbGeAlD
Carvedilol—ABCB1—renal system—uterine cancer	0.000107	0.00107	CbGeAlD
Carvedilol—Hyponatraemia—Doxorubicin—uterine cancer	0.000106	0.000883	CcSEcCtD
Carvedilol—Hypertension—Etoposide—uterine cancer	0.000106	0.000882	CcSEcCtD
Carvedilol—Pain in extremity—Doxorubicin—uterine cancer	0.000105	0.00088	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000105	0.00088	CcSEcCtD
Carvedilol—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000105	0.000877	CcSEcCtD
Carvedilol—Chest pain—Etoposide—uterine cancer	0.000104	0.000869	CcSEcCtD
Carvedilol—Orthostatic hypotension—Epirubicin—uterine cancer	0.000104	0.000868	CcSEcCtD
Carvedilol—Migraine—Doxorubicin—uterine cancer	0.000104	0.000866	CcSEcCtD
Carvedilol—Affect lability—Doxorubicin—uterine cancer	0.000104	0.000866	CcSEcCtD
Carvedilol—Hypokalaemia—Epirubicin—uterine cancer	0.000104	0.000865	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000103	0.000864	CcSEcCtD
Carvedilol—ABCB1—endometrium—uterine cancer	0.000103	0.00104	CbGeAlD
Carvedilol—Discomfort—Etoposide—uterine cancer	0.000103	0.000859	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000103	0.000856	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000103	0.000856	CcSEcCtD
Carvedilol—Nasopharyngitis—Epirubicin—uterine cancer	0.000102	0.00085	CcSEcCtD
Carvedilol—Hypersensitivity—Dactinomycin—uterine cancer	0.000102	0.000849	CcSEcCtD
Carvedilol—Confusional state—Etoposide—uterine cancer	0.000101	0.00084	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.0001	0.000838	CcSEcCtD
Carvedilol—Cardiac arrest—Doxorubicin—uterine cancer	0.0001	0.000836	CcSEcCtD
Carvedilol—Anaphylactic shock—Etoposide—uterine cancer	9.99e-05	0.000834	CcSEcCtD
Carvedilol—Mood swings—Doxorubicin—uterine cancer	9.98e-05	0.000833	CcSEcCtD
Carvedilol—ABCB1—mammalian vulva—uterine cancer	9.97e-05	0.001	CbGeAlD
Carvedilol—Infection—Etoposide—uterine cancer	9.92e-05	0.000828	CcSEcCtD
Carvedilol—Asthenia—Dactinomycin—uterine cancer	9.9e-05	0.000826	CcSEcCtD
Carvedilol—Blood creatinine increased—Doxorubicin—uterine cancer	9.87e-05	0.000824	CcSEcCtD
Carvedilol—Influenza—Epirubicin—uterine cancer	9.85e-05	0.000822	CcSEcCtD
Carvedilol—Dehydration—Doxorubicin—uterine cancer	9.8e-05	0.000818	CcSEcCtD
Carvedilol—Thrombocytopenia—Etoposide—uterine cancer	9.78e-05	0.000816	CcSEcCtD
Carvedilol—Tachycardia—Etoposide—uterine cancer	9.75e-05	0.000814	CcSEcCtD
Carvedilol—Skin disorder—Etoposide—uterine cancer	9.7e-05	0.00081	CcSEcCtD
Carvedilol—Hyperhidrosis—Etoposide—uterine cancer	9.66e-05	0.000806	CcSEcCtD
Carvedilol—Orthostatic hypotension—Doxorubicin—uterine cancer	9.63e-05	0.000803	CcSEcCtD
Carvedilol—CYP1A1—lymph node—uterine cancer	9.62e-05	0.000969	CbGeAlD
Carvedilol—Hypokalaemia—Doxorubicin—uterine cancer	9.59e-05	0.000801	CcSEcCtD
Carvedilol—Angina pectoris—Epirubicin—uterine cancer	9.59e-05	0.0008	CcSEcCtD
Carvedilol—Anorexia—Etoposide—uterine cancer	9.52e-05	0.000795	CcSEcCtD
Carvedilol—ABCB1—uterus—uterine cancer	9.5e-05	0.000957	CbGeAlD
Carvedilol—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	9.49e-05	0.000792	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	9.49e-05	0.000792	CcSEcCtD
Carvedilol—Bronchitis—Epirubicin—uterine cancer	9.47e-05	0.00079	CcSEcCtD
Carvedilol—Diarrhoea—Dactinomycin—uterine cancer	9.44e-05	0.000788	CcSEcCtD
Carvedilol—Nasopharyngitis—Doxorubicin—uterine cancer	9.42e-05	0.000787	CcSEcCtD
Carvedilol—Pancytopenia—Epirubicin—uterine cancer	9.35e-05	0.00078	CcSEcCtD
Carvedilol—Hypotension—Etoposide—uterine cancer	9.33e-05	0.000779	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Doxorubicin—uterine cancer	9.3e-05	0.000776	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Epirubicin—uterine cancer	9.15e-05	0.000764	CcSEcCtD
Carvedilol—Influenza—Doxorubicin—uterine cancer	9.11e-05	0.00076	CcSEcCtD
Carvedilol—Pollakiuria—Epirubicin—uterine cancer	9.09e-05	0.000759	CcSEcCtD
Carvedilol—Photosensitivity reaction—Epirubicin—uterine cancer	8.99e-05	0.00075	CcSEcCtD
Carvedilol—Paraesthesia—Etoposide—uterine cancer	8.97e-05	0.000748	CcSEcCtD
Carvedilol—ADRA2A—lymph node—uterine cancer	8.97e-05	0.000904	CbGeAlD
Carvedilol—Weight increased—Epirubicin—uterine cancer	8.96e-05	0.000748	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—uterine cancer	8.91e-05	0.000743	CcSEcCtD
Carvedilol—Dyspnoea—Etoposide—uterine cancer	8.9e-05	0.000743	CcSEcCtD
Carvedilol—Hyperglycaemia—Epirubicin—uterine cancer	8.88e-05	0.000741	CcSEcCtD
Carvedilol—Somnolence—Etoposide—uterine cancer	8.88e-05	0.000741	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—uterine cancer	8.87e-05	0.000741	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—uterine cancer	8.83e-05	0.000737	CcSEcCtD
Carvedilol—Vomiting—Dactinomycin—uterine cancer	8.77e-05	0.000732	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—uterine cancer	8.76e-05	0.000731	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—uterine cancer	8.7e-05	0.000726	CcSEcCtD
Carvedilol—Rash—Dactinomycin—uterine cancer	8.7e-05	0.000726	CcSEcCtD
Carvedilol—Decreased appetite—Etoposide—uterine cancer	8.68e-05	0.000725	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—uterine cancer	8.65e-05	0.000722	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—uterine cancer	8.63e-05	0.00072	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Etoposide—uterine cancer	8.62e-05	0.00072	CcSEcCtD
Carvedilol—Fatigue—Etoposide—uterine cancer	8.61e-05	0.000719	CcSEcCtD
Carvedilol—ABCB1—female reproductive system—uterine cancer	8.54e-05	0.000861	CbGeAlD
Carvedilol—Pain—Etoposide—uterine cancer	8.54e-05	0.000713	CcSEcCtD
Carvedilol—Constipation—Etoposide—uterine cancer	8.54e-05	0.000713	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—uterine cancer	8.53e-05	0.000712	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—uterine cancer	8.47e-05	0.000707	CcSEcCtD
Carvedilol—PTGS1—lymph node—uterine cancer	8.45e-05	0.000852	CbGeAlD
Carvedilol—Pollakiuria—Doxorubicin—uterine cancer	8.42e-05	0.000702	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—uterine cancer	8.37e-05	0.000698	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—uterine cancer	8.31e-05	0.000694	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—uterine cancer	8.29e-05	0.000692	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—uterine cancer	8.24e-05	0.000688	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—uterine cancer	8.24e-05	0.000687	CcSEcCtD
Carvedilol—Feeling abnormal—Etoposide—uterine cancer	8.23e-05	0.000687	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—uterine cancer	8.22e-05	0.000686	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—uterine cancer	8.2e-05	0.000684	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—uterine cancer	8.17e-05	0.000682	CcSEcCtD
Carvedilol—Gastrointestinal pain—Etoposide—uterine cancer	8.17e-05	0.000682	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	8.05e-05	0.000672	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—uterine cancer	8.02e-05	0.00067	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—uterine cancer	7.98e-05	0.000666	CcSEcCtD
Carvedilol—Urticaria—Etoposide—uterine cancer	7.93e-05	0.000662	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—uterine cancer	7.92e-05	0.000661	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—uterine cancer	7.9e-05	0.000659	CcSEcCtD
Carvedilol—Abdominal pain—Etoposide—uterine cancer	7.9e-05	0.000659	CcSEcCtD
Carvedilol—Body temperature increased—Etoposide—uterine cancer	7.9e-05	0.000659	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—uterine cancer	7.89e-05	0.000659	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—uterine cancer	7.88e-05	0.000658	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—uterine cancer	7.84e-05	0.000654	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—uterine cancer	7.82e-05	0.000653	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—uterine cancer	7.78e-05	0.000649	CcSEcCtD
Carvedilol—ABCB1—female gonad—uterine cancer	7.77e-05	0.000783	CbGeAlD
Carvedilol—Oedema peripheral—Epirubicin—uterine cancer	7.76e-05	0.000648	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—uterine cancer	7.74e-05	0.000646	CcSEcCtD
Carvedilol—ABCB1—vagina—uterine cancer	7.72e-05	0.000778	CbGeAlD
Carvedilol—Urethral disorder—Epirubicin—uterine cancer	7.72e-05	0.000645	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—uterine cancer	7.62e-05	0.000636	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—uterine cancer	7.59e-05	0.000634	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—uterine cancer	7.45e-05	0.000622	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—uterine cancer	7.42e-05	0.000619	CcSEcCtD
Carvedilol—Hypersensitivity—Etoposide—uterine cancer	7.36e-05	0.000614	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—uterine cancer	7.35e-05	0.000613	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—uterine cancer	7.33e-05	0.000612	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—uterine cancer	7.31e-05	0.00061	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—uterine cancer	7.29e-05	0.000609	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—uterine cancer	7.25e-05	0.000605	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—uterine cancer	7.24e-05	0.000604	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—uterine cancer	7.2e-05	0.000601	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—uterine cancer	7.18e-05	0.000599	CcSEcCtD
Carvedilol—Asthenia—Etoposide—uterine cancer	7.17e-05	0.000598	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—uterine cancer	7.15e-05	0.000597	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—uterine cancer	7.15e-05	0.000596	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—uterine cancer	7.12e-05	0.000594	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—uterine cancer	7.1e-05	0.000593	CcSEcCtD
Carvedilol—Pruritus—Etoposide—uterine cancer	7.07e-05	0.00059	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—uterine cancer	7.03e-05	0.000586	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—uterine cancer	6.96e-05	0.000581	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—uterine cancer	6.89e-05	0.000575	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—uterine cancer	6.86e-05	0.000572	CcSEcCtD
Carvedilol—Diarrhoea—Etoposide—uterine cancer	6.83e-05	0.00057	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—uterine cancer	6.8e-05	0.000567	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—uterine cancer	6.76e-05	0.000564	CcSEcCtD
Carvedilol—Tension—Epirubicin—uterine cancer	6.73e-05	0.000562	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—uterine cancer	6.66e-05	0.000556	CcSEcCtD
Carvedilol—Back pain—Epirubicin—uterine cancer	6.64e-05	0.000554	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—uterine cancer	6.62e-05	0.000552	CcSEcCtD
Carvedilol—Dizziness—Etoposide—uterine cancer	6.6e-05	0.000551	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—uterine cancer	6.6e-05	0.00055	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—uterine cancer	6.59e-05	0.00055	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—uterine cancer	6.57e-05	0.000548	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—uterine cancer	6.46e-05	0.00054	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—uterine cancer	6.44e-05	0.000538	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—uterine cancer	6.36e-05	0.000531	CcSEcCtD
Carvedilol—Vomiting—Etoposide—uterine cancer	6.35e-05	0.00053	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—uterine cancer	6.35e-05	0.00053	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—uterine cancer	6.34e-05	0.000529	CcSEcCtD
Carvedilol—Rash—Etoposide—uterine cancer	6.3e-05	0.000526	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—uterine cancer	6.29e-05	0.000525	CcSEcCtD
Carvedilol—Headache—Etoposide—uterine cancer	6.26e-05	0.000522	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—uterine cancer	6.25e-05	0.000522	CcSEcCtD
Carvedilol—Tension—Doxorubicin—uterine cancer	6.23e-05	0.00052	CcSEcCtD
Carvedilol—Malaise—Epirubicin—uterine cancer	6.19e-05	0.000516	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—uterine cancer	6.16e-05	0.000514	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—uterine cancer	6.16e-05	0.000514	CcSEcCtD
Carvedilol—Syncope—Epirubicin—uterine cancer	6.15e-05	0.000513	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—uterine cancer	6.14e-05	0.000512	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—uterine cancer	6.14e-05	0.000512	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—uterine cancer	6.1e-05	0.000509	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—uterine cancer	6.06e-05	0.000506	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—uterine cancer	6.03e-05	0.000503	CcSEcCtD
Carvedilol—Cough—Epirubicin—uterine cancer	5.99e-05	0.0005	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—uterine cancer	5.98e-05	0.000499	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—uterine cancer	5.94e-05	0.000496	CcSEcCtD
Carvedilol—Nausea—Etoposide—uterine cancer	5.93e-05	0.000495	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—uterine cancer	5.92e-05	0.000494	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—uterine cancer	5.89e-05	0.000491	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—uterine cancer	5.87e-05	0.00049	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—uterine cancer	5.84e-05	0.000487	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—uterine cancer	5.84e-05	0.000487	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—uterine cancer	5.84e-05	0.000487	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	5.8e-05	0.000484	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—uterine cancer	5.77e-05	0.000482	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—uterine cancer	5.72e-05	0.000478	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—uterine cancer	5.71e-05	0.000477	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—uterine cancer	5.7e-05	0.000476	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—uterine cancer	5.69e-05	0.000475	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—uterine cancer	5.68e-05	0.000474	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—uterine cancer	5.65e-05	0.000471	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—uterine cancer	5.61e-05	0.000468	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—uterine cancer	5.6e-05	0.000467	CcSEcCtD
Carvedilol—Oedema—Epirubicin—uterine cancer	5.6e-05	0.000467	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—uterine cancer	5.58e-05	0.000466	CcSEcCtD
Carvedilol—Infection—Epirubicin—uterine cancer	5.56e-05	0.000464	CcSEcCtD
Carvedilol—Cough—Doxorubicin—uterine cancer	5.54e-05	0.000462	CcSEcCtD
Carvedilol—Shock—Epirubicin—uterine cancer	5.51e-05	0.00046	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—uterine cancer	5.5e-05	0.000459	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—uterine cancer	5.48e-05	0.000457	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—uterine cancer	5.48e-05	0.000457	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—uterine cancer	5.46e-05	0.000456	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—uterine cancer	5.44e-05	0.000454	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—uterine cancer	5.41e-05	0.000452	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—uterine cancer	5.4e-05	0.000451	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—uterine cancer	5.4e-05	0.000451	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—uterine cancer	5.4e-05	0.000451	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.37e-05	0.000448	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—uterine cancer	5.34e-05	0.000446	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—uterine cancer	5.34e-05	0.000445	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—uterine cancer	5.28e-05	0.000441	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—uterine cancer	5.23e-05	0.000437	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—uterine cancer	5.22e-05	0.000436	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—uterine cancer	5.18e-05	0.000432	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—uterine cancer	5.18e-05	0.000432	CcSEcCtD
Carvedilol—Infection—Doxorubicin—uterine cancer	5.15e-05	0.000429	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.1e-05	0.000426	CcSEcCtD
Carvedilol—Shock—Doxorubicin—uterine cancer	5.1e-05	0.000425	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—uterine cancer	5.07e-05	0.000423	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—uterine cancer	5.06e-05	0.000423	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—uterine cancer	5.06e-05	0.000422	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—uterine cancer	5.03e-05	0.00042	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—uterine cancer	5.03e-05	0.00042	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—uterine cancer	5.01e-05	0.000418	CcSEcCtD
Carvedilol—ABCB1—lymph node—uterine cancer	5e-05	0.000503	CbGeAlD
Carvedilol—Dyspnoea—Epirubicin—uterine cancer	4.99e-05	0.000417	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—uterine cancer	4.98e-05	0.000415	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—uterine cancer	4.94e-05	0.000412	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—uterine cancer	4.93e-05	0.000411	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—uterine cancer	4.87e-05	0.000406	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—uterine cancer	4.84e-05	0.000404	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—uterine cancer	4.83e-05	0.000403	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—uterine cancer	4.83e-05	0.000403	CcSEcCtD
Carvedilol—Pain—Epirubicin—uterine cancer	4.79e-05	0.0004	CcSEcCtD
Carvedilol—Constipation—Epirubicin—uterine cancer	4.79e-05	0.0004	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.72e-05	0.000394	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—uterine cancer	4.69e-05	0.000391	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—uterine cancer	4.65e-05	0.000388	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—uterine cancer	4.62e-05	0.000385	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—uterine cancer	4.61e-05	0.000385	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—uterine cancer	4.61e-05	0.000384	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—uterine cancer	4.58e-05	0.000382	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—uterine cancer	4.56e-05	0.000381	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—uterine cancer	4.5e-05	0.000376	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.47e-05	0.000373	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—uterine cancer	4.47e-05	0.000373	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—uterine cancer	4.45e-05	0.000371	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—uterine cancer	4.43e-05	0.00037	CcSEcCtD
Carvedilol—Pain—Doxorubicin—uterine cancer	4.43e-05	0.00037	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—uterine cancer	4.43e-05	0.000369	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—uterine cancer	4.43e-05	0.000369	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—uterine cancer	4.27e-05	0.000356	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—uterine cancer	4.24e-05	0.000354	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—uterine cancer	4.12e-05	0.000344	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—uterine cancer	4.12e-05	0.000343	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—uterine cancer	4.1e-05	0.000342	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—uterine cancer	4.1e-05	0.000342	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—uterine cancer	4.02e-05	0.000335	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—uterine cancer	3.96e-05	0.000331	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—uterine cancer	3.83e-05	0.00032	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—uterine cancer	3.82e-05	0.000319	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—uterine cancer	3.72e-05	0.00031	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—uterine cancer	3.7e-05	0.000309	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—uterine cancer	3.66e-05	0.000306	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—uterine cancer	3.56e-05	0.000297	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—uterine cancer	3.54e-05	0.000296	CcSEcCtD
Carvedilol—Rash—Epirubicin—uterine cancer	3.53e-05	0.000295	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—uterine cancer	3.53e-05	0.000294	CcSEcCtD
Carvedilol—Headache—Epirubicin—uterine cancer	3.51e-05	0.000293	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—uterine cancer	3.43e-05	0.000286	CcSEcCtD
Carvedilol—Nausea—Epirubicin—uterine cancer	3.33e-05	0.000278	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—uterine cancer	3.29e-05	0.000275	CcSEcCtD
Carvedilol—Rash—Doxorubicin—uterine cancer	3.27e-05	0.000273	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—uterine cancer	3.26e-05	0.000272	CcSEcCtD
Carvedilol—Headache—Doxorubicin—uterine cancer	3.25e-05	0.000271	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—uterine cancer	3.08e-05	0.000257	CcSEcCtD
Carvedilol—CYP2E1—Metabolism—MTHFR—uterine cancer	4.61e-06	5.26e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ESR1—uterine cancer	4.6e-06	5.24e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—uterine cancer	4.59e-06	5.24e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMAD3—uterine cancer	4.58e-06	5.22e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ESR1—uterine cancer	4.52e-06	5.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—uterine cancer	4.5e-06	5.13e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—PIK3CA—uterine cancer	4.49e-06	5.12e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—uterine cancer	4.44e-06	5.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCL8—uterine cancer	4.4e-06	5.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL2—uterine cancer	4.37e-06	4.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGFR2—uterine cancer	4.36e-06	4.98e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—STK11—uterine cancer	4.36e-06	4.97e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP19A1—uterine cancer	4.36e-06	4.97e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—MTHFR—uterine cancer	4.35e-06	4.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—uterine cancer	4.35e-06	4.96e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL2—uterine cancer	4.33e-06	4.94e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—STK11—uterine cancer	4.32e-06	4.93e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.32e-06	4.93e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL2—uterine cancer	4.28e-06	4.88e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—uterine cancer	4.28e-06	4.88e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—RRM2—uterine cancer	4.23e-06	4.83e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—AKT1—uterine cancer	4.23e-06	4.82e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—DCN—uterine cancer	4.11e-06	4.69e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—PIK3CA—uterine cancer	4.09e-06	4.66e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—PIK3CA—uterine cancer	4.07e-06	4.65e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.05e-06	4.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—PIK3CA—uterine cancer	4.05e-06	4.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL2—uterine cancer	4.05e-06	4.62e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—uterine cancer	4.04e-06	4.61e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—uterine cancer	4.02e-06	4.59e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ESR1—uterine cancer	4.02e-06	4.58e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—uterine cancer	4.01e-06	4.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—uterine cancer	4e-06	4.57e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—uterine cancer	4e-06	4.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—PIK3CA—uterine cancer	4e-06	4.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL2—uterine cancer	3.98e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—AKT1—uterine cancer	3.97e-06	4.53e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—uterine cancer	3.95e-06	4.51e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP11A1—uterine cancer	3.87e-06	4.42e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.87e-06	4.41e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.83e-06	4.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—uterine cancer	3.8e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL8—uterine cancer	3.79e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—PIK3CA—uterine cancer	3.78e-06	4.32e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—uterine cancer	3.77e-06	4.3e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—uterine cancer	3.74e-06	4.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ESR1—uterine cancer	3.73e-06	4.26e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—PIK3CA—uterine cancer	3.72e-06	4.25e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PIK3CA—uterine cancer	3.71e-06	4.23e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CDKN1B—uterine cancer	3.71e-06	4.23e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PIK3CA—uterine cancer	3.7e-06	4.21e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—STK11—uterine cancer	3.69e-06	4.21e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP19A1—uterine cancer	3.69e-06	4.21e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PIK3CA—uterine cancer	3.69e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—uterine cancer	3.68e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PIK3CA—uterine cancer	3.68e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—AKT1—uterine cancer	3.67e-06	4.18e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKR1C3—uterine cancer	3.66e-06	4.17e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—uterine cancer	3.65e-06	4.16e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PIK3CA—uterine cancer	3.63e-06	4.14e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—uterine cancer	3.61e-06	4.12e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—uterine cancer	3.57e-06	4.08e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—uterine cancer	3.57e-06	4.07e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—uterine cancer	3.57e-06	4.07e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL2—uterine cancer	3.54e-06	4.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—uterine cancer	3.53e-06	4.03e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CTNNB1—uterine cancer	3.5e-06	3.99e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MTHFR—uterine cancer	3.47e-06	3.96e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.46e-06	3.95e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL8—uterine cancer	3.46e-06	3.94e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTEN—uterine cancer	3.44e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PIK3CA—uterine cancer	3.44e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—uterine cancer	3.44e-06	3.92e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTEN—uterine cancer	3.43e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL8—uterine cancer	3.43e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—uterine cancer	3.42e-06	3.9e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—uterine cancer	3.41e-06	3.89e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—uterine cancer	3.41e-06	3.89e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—uterine cancer	3.4e-06	3.88e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL8—uterine cancer	3.38e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CA—uterine cancer	3.38e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CDKN1B—uterine cancer	3.38e-06	3.85e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—uterine cancer	3.37e-06	3.85e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—uterine cancer	3.36e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDKN1B—uterine cancer	3.35e-06	3.82e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKT1—uterine cancer	3.34e-06	3.81e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKT1—uterine cancer	3.33e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—uterine cancer	3.32e-06	3.79e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKT1—uterine cancer	3.31e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CA—uterine cancer	3.31e-06	3.77e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.3e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDKN1B—uterine cancer	3.3e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL2—uterine cancer	3.29e-06	3.75e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—EP300—uterine cancer	3.28e-06	3.74e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—EP300—uterine cancer	3.28e-06	3.74e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MTHFR—uterine cancer	3.27e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—uterine cancer	3.27e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—uterine cancer	3.27e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EP300—uterine cancer	3.25e-06	3.71e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MTHFR—uterine cancer	3.25e-06	3.7e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—uterine cancer	3.2e-06	3.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—uterine cancer	3.19e-06	3.64e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—uterine cancer	3.18e-06	3.63e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—uterine cancer	3.16e-06	3.6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—uterine cancer	3.15e-06	3.59e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—uterine cancer	3.13e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1B—uterine cancer	3.13e-06	3.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—uterine cancer	3.12e-06	3.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—uterine cancer	3.11e-06	3.55e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—uterine cancer	3.09e-06	3.53e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—uterine cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—uterine cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1B—uterine cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—uterine cancer	3.07e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—uterine cancer	3.04e-06	3.47e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—uterine cancer	3.04e-06	3.47e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—uterine cancer	3.04e-06	3.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—uterine cancer	3.04e-06	3.46e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—uterine cancer	3.03e-06	3.46e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—uterine cancer	3.02e-06	3.44e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—uterine cancer	3.01e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—uterine cancer	3.01e-06	3.43e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—uterine cancer	3e-06	3.43e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—uterine cancer	2.97e-06	3.38e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EP300—uterine cancer	2.96e-06	3.38e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—uterine cancer	2.95e-06	3.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	2.95e-06	3.36e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EP300—uterine cancer	2.94e-06	3.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—uterine cancer	2.91e-06	3.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EP300—uterine cancer	2.9e-06	3.31e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—uterine cancer	2.88e-06	3.28e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.86e-06	3.26e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—STK11—uterine cancer	2.85e-06	3.25e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.85e-06	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—uterine cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—uterine cancer	2.81e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—uterine cancer	2.81e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	2.8e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—uterine cancer	2.8e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	2.79e-06	3.18e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	2.78e-06	3.17e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	2.78e-06	3.17e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—uterine cancer	2.77e-06	3.16e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—uterine cancer	2.77e-06	3.16e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—uterine cancer	2.76e-06	3.15e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—uterine cancer	2.75e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—uterine cancer	2.75e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EP300—uterine cancer	2.74e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	2.74e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	2.73e-06	3.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—uterine cancer	2.71e-06	3.09e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	2.7e-06	3.08e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EP300—uterine cancer	2.7e-06	3.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—EP300—uterine cancer	2.67e-06	3.04e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—uterine cancer	2.62e-06	2.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	2.6e-06	2.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—uterine cancer	2.6e-06	2.96e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	2.58e-06	2.94e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	2.58e-06	2.94e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—uterine cancer	2.57e-06	2.93e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—uterine cancer	2.57e-06	2.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—uterine cancer	2.56e-06	2.92e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	2.54e-06	2.89e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—uterine cancer	2.53e-06	2.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—uterine cancer	2.52e-06	2.87e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	2.51e-06	2.86e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	2.45e-06	2.8e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—EP300—uterine cancer	2.45e-06	2.79e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.44e-06	2.79e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—uterine cancer	2.43e-06	2.77e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—uterine cancer	2.42e-06	2.76e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—uterine cancer	2.42e-06	2.76e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—uterine cancer	2.41e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EP300—uterine cancer	2.4e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	2.4e-06	2.73e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—uterine cancer	2.39e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—uterine cancer	2.37e-06	2.7e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—uterine cancer	2.34e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—uterine cancer	2.34e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—uterine cancer	2.33e-06	2.66e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—EP300—uterine cancer	2.31e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	2.28e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	2.27e-06	2.59e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—uterine cancer	2.24e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EP300—uterine cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—uterine cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—uterine cancer	2.21e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—uterine cancer	2.19e-06	2.5e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—uterine cancer	2.17e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	2.17e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—uterine cancer	2.15e-06	2.45e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—uterine cancer	2.14e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—uterine cancer	2.12e-06	2.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	2.11e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—uterine cancer	2.1e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—uterine cancer	2.09e-06	2.38e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—uterine cancer	2.08e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—uterine cancer	2.03e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—uterine cancer	2.03e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—uterine cancer	2.01e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—uterine cancer	2e-06	2.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—uterine cancer	1.98e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—uterine cancer	1.98e-06	2.26e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—uterine cancer	1.98e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—uterine cancer	1.97e-06	2.25e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—uterine cancer	1.97e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—uterine cancer	1.96e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—uterine cancer	1.93e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—uterine cancer	1.93e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—uterine cancer	1.93e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—uterine cancer	1.88e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—uterine cancer	1.85e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—EP300—uterine cancer	1.84e-06	2.1e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—uterine cancer	1.82e-06	2.08e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—uterine cancer	1.81e-06	2.06e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—uterine cancer	1.81e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—uterine cancer	1.79e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—uterine cancer	1.79e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—uterine cancer	1.78e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	1.77e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—uterine cancer	1.75e-06	2e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—EP300—uterine cancer	1.74e-06	1.98e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—EP300—uterine cancer	1.72e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—uterine cancer	1.72e-06	1.96e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—uterine cancer	1.71e-06	1.95e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—uterine cancer	1.66e-06	1.89e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	1.65e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—uterine cancer	1.64e-06	1.87e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—uterine cancer	1.63e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—uterine cancer	1.61e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—uterine cancer	1.6e-06	1.82e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—uterine cancer	1.54e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—uterine cancer	1.53e-06	1.74e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—uterine cancer	1.48e-06	1.69e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—EP300—uterine cancer	1.47e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—uterine cancer	1.45e-06	1.65e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—uterine cancer	1.39e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—uterine cancer	1.36e-06	1.55e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—uterine cancer	1.35e-06	1.54e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.28e-06	1.47e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.27e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—uterine cancer	1.19e-06	1.36e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—EP300—uterine cancer	1.14e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—uterine cancer	1.11e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.09e-06	1.24e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—uterine cancer	1.05e-06	1.2e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—uterine cancer	1.04e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—uterine cancer	8.89e-07	1.01e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—uterine cancer	8.4e-07	9.58e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—uterine cancer	6.86e-07	7.83e-06	CbGpPWpGaD
